Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~Patients with type 2 diabetes (drug naive or pre-treated) with insufficient glycaemic control (HbA1c higher or equal than 7.5 to less than 11.0 %), with very poor glycaemic control (HbA1c higher or equal than 11.0 %) who are not eligible for randomisation to be included in the open-label arm~Exclusion criteria:~Myocardial infarction, stroke or transient ischemic attack (TIA), unstable or acute congestive heart failure, impaired hepatic function, treatment with rosiglitazone or pioglitazone, with a GLP1 analogue, with insulin, with anti-obesity drugs, with systemic steroids, renal failure or impairment, gastric bypass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 + metformin (Type: EXPERIMENTAL): BI 1356 low dose + metformin 500 mg, twice daily
- matching placebo (Type: PLACEBO_COMPARATOR): matching placebo
- BI 1356+ Metformin (Type: EXPERIMENTAL): BI 1356 low dose + metformin 1000 mg, twice daily
- Metformin (Type: ACTIVE_COMPARATOR): Metformin 500 mg, twice daily
- metformin (Type: ACTIVE_COMPARATOR): Metformin 1000 mg, twice daily
- BI 1356 (Type: EXPERIMENTAL): BI 1356 high dose, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).